A. Fujimori

发表

Altered topoisomerase I expression in two subclones of human CEM leukemia selected for resistance to camptothecin.

Y. Pommier, D. Slade, W. G. Harker, 1995, Oncology research.

Cellular Determinants of Sensitivity and Resistance to DNA Topoisomerase Inhibitors

K. Kohn, Y. Pommier, E. Solary, 1994 .

Acquired camptothecin resistance of human breast cancer MCF-7/C4 cells with normal topoisomerase I and elevated DNA repair.

Y. Pommier, Y. Hoki, M. Gupta, 1996, Molecular pharmacology.

Silencing and selective methylation of the normal topoisomerase I gene in camptothecin-resistant CEM/C2 human leukemia cells.

Y. Pommier, Y. Hoki, N. Popescu, 1996, Oncology research.

Eukaryotic DNA topoisomerases I.

Y. Pommier, A. Fujimori, Y Pommier, 1995, Biochimica et biophysica acta.

Comparison of topoisomerase I inhibition, DNA damage, and cytotoxicity of camptothecin derivatives presently in clinical trials.

Y. Pommier, A. Fujimori, Y. Fujimori, 1994, Journal of the National Cancer Institute.

IncreasedNuclear Localizationof Transcription Factor Y-Box Binding Protein 1 Accompanied by Up-Regulation of P-glycoprotein in Breast Cancer Pretreatedwith Paclitaxel

H. Izumi, K. Kohno, H. Nakagomi, 2005 .

Mutation at the catalytic site of topoisomerase I in CEM/C2, a human leukemia cell line resistant to camptothecin.

Y. Pommier, Y. Hoki, G. Kohlhagen, 1995, Cancer research.

Saintopin, a dual inhibitor of DNA topoisomerases I and II, as a probe for drug-enzyme interactions.

Y. Pommier, H. Nakano, G. Kohlhagen, 1994, The Journal of biological chemistry.